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ABSTRACT 34 
Medication adherence-related research applies observational, interventional and/or implementation 35 
science approaches spanning multiple disciplines to assess or manage medication adherence. This 36 
demands coherent conceptualization, valid methods, appropriate analyses, and complete, accurate 37 
reporting. To ensure reliable reporting, the European Society for Patient Adherence, Compliance and 38 
Persistence (ESPACOMP) Medication Adherence Reporting Guideline (EMERGE) recommends 39 
standard reporting approaches based on an accepted taxonomy.  40 
This guideline results from a literature review, a reactive e-Delphi study with 26 international 41 
multidisciplinary medication adherence experts, and feedback from the ESPACOMP membership. It 42 
is designed to supplement existing guidelines for health research reporting, and structured around 4 43 
minimum reporting criteria and 17 items reflecting best reporting practice. By enhancing and 44 
harmonizing research reporting, EMERGE aims to advance research and, ultimately, patient 45 
outcomes.  46 
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CHALLENGES AND SHORTCOMINGS IN MEDICATION ADHERENCE REPORTING 47 
Medication non-adherence is a major public health problem(1, 2) with significant health and 48 
economic consequences.(1-4) For many conditions, taking medications as prescribed is crucial to 49 
achieve optimal outcomes.(5-7) Despite more than 50 years of research, the evidence base for 50 
effective interventions that can be implemented in routine clinical care remains limited.(8, 9)  51 
Medication adherence-related research applies observational, interventional and/or implementation 52 
science approaches across disciplines including, but not limited to medicine, pharmacy, nursing, 53 
behavioral science, sociology, pharmacometrics, biostatistics and health economics.(10) 54 
Unfortunately, inadequate research reporting often hampers interpretation of findings, complicates 55 
data abstraction for meta-analyses and prevents study replication. Common problems of reporting 56 
include unclear, inconsistent definitions;(11-14) inadequate measurement of adherence 57 
outcomes;(7, 14, 15) suboptimal methods of analysis;(11-14) insufficiently detailed descriptions of 58 
intervention delivery settings;(15) and scant theoretical underpinnings.(16) 59 
Previous efforts to improve adherence research reporting standards(11, 17-20), have resulted in 60 
guidelines and recommendations that overlap with existing health research reporting guidelines, 61 
e.g., CONsolidated Standards of Reporting Trials (CONSORT),(21) STrengthening the Reporting of 62 
OBservational studies in Epidemiology (STROBE),(22) Standards for Reporting Implementation 63 
Studies (StaRI) Statement (StaRI).(23) These recommendations only indirectly pertain to medication 64 
adherence research,(17, 19) include no clear conceptualization of medication adherence(11, 17, 19, 65 
20) and focus on research methods rather than reporting.(11, 19, 20) 66 
Weighing these shortcomings against evidence that guidelines endorsed by professional societies 67 
and journals enhance overall health research reporting,(24-28) the European Society for Patient 68 
Adherence, COMpliance, and Persistence (ESPACOMP, www.espacomp.eu, accessed: April 30th, 69 
2018) developed the ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Grounded in 70 
the conceptualization of medication adherence provided by the previously-reported taxonomy,(10) 71 
EMERGE aims to complement existing health research reporting guidelines, increasing the 72 
transparency and consistency of reporting by guiding researchers through processes specifically 73 
relevant to medication adherence, as well as to those for which it is a variable of interest. 74 
Taxonomy for medication adherence 75 
EMERGE adopts the previously-reported taxonomy(10) which defines medication adherence as “the 76 
process by which patients take their medications as prescribed,” consisting of three interrelated yet 77 
distinct phases: (A) initiation; (B) implementation; and (C) persistence (figure 1). Non-adherence to 78 
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medications can occur in any of these phases, e.g., late, incomplete, or non-initiation of the 79 
prescribed treatment, sub-optimal implementation of the dosing regimen (e.g., late, skipped, extra 80 
or reduced doses, drug holidays) or early discontinuation (non-persistence). Each phase poses 81 
different methodological challenges related to how medication use is operationally defined, 82 
measured, and analyzed. 83 
DEVELOPMENT OF EMERGE 84 
EMERGE was developed in accordance with recommendations for health research reporting 85 
guideline developers(29) of the Enhancing the QUAlity and Transparency Of health Research 86 
(EQUATOR) network (www.equator-network.org, accessed: April 30th, 2018). The methods for 87 
developing EMERGE have been previously published.(30) Briefly, a steering committee comprised of 88 
7 members of ESPACOMP (SDG, LLZ, JDJ, RH, DAH, IBW, BV) led the project. The committee first 89 
convened in Prague, Czech Republic in 2015, followed by 4 feedback rounds via email and 90 
conference calls in 2016. Their discussion of a literature review of published adherence guidelines 91 
and a further review of existing health research reporting guidelines(21-23, 31) yielded an initial pool 92 
of 26 items (i.e., statements) organized according to the sections of the most used health research 93 
reporting guidelines (i.e., CONSORT, STROBE). To avoid redundancy and facilitate EMERGE’s 94 
applicability across the various study designs, the committee considered overlap with existing 95 
guidelines throughout the development process.(30) 96 
The initial 26-item pool was the basis of two rounds of reactive e-Delphi surveys.(32, 33) A purposive 97 
sample of 45 international experts (across 15 countries, 6 continents), representing diverse 98 
disciplines and fields engaged in medication adherence research was selected and invited to 99 
participate (i.e., 17 in clinical research, 14 in health services research, 13 in public health, 11 in 100 
medicine, 9 in behavioral medicine/health psychology, 6 in journal editing, 5 in health policy, 5 in 101 
pharmacoepidemiology, 5 in statistics, 4 in nursing, 4 in pharmacy / pharmaceutical sciences, 3 in 102 
clinical pharmacology, 2 in the pharmaceutical industry and 6 in other fields; on average, experts 103 
belonged to about 4 disciplines). Of the 45 experts, 29 participated in the first round (64% response 104 
rate). They evaluated each item for relevance and clarity, and could comment, suggest further items 105 
and/or modify the initial items. Guided by pre-defined rules(30) as well as by qualitative comments 106 
received from the survey experts, the steering committee reviewed and discussed the first-round e-107 
Delphi results during a meeting in Húsafell, Iceland in July 2016. 108 
Based on the agreed criteria, all 26 items initially evaluated in the first Delphi round were judged 109 
relevant (mean 91%, SD 5%, range: 79%-97%) and clear (mean 84%, SD 10% range: 59%-97%). 110 
Nevertheless, the experts’ qualitative comments and subsequent discussion in the steering 111 
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committee presented opportunities to optimize the wording of several items. The committee 112 
consequently chose to exclude 5 items due to redundancy or inconsistency with other EMERGE 113 
items, or with items from the main reporting guidelines. 114 
The remaining 21 items entered the second e-Delphi round, during which 26 of the 29 (90%) experts 115 
who participated in the first round re-rated the items for relevance and clarity. All items again 116 
cleared the threshold for relevance (mean 93%, range: 85%-100%) and clarity (mean 90%, range: 117 
73%-100%). The qualitative comments allowed fine-tuning of several items’ wording, resulting in the 118 
21-item list presented at the annual ESPACOMP conference in Lisbon, Portugal in November 2016 119 
and approved by a formal vote of all members. 120 
ESPACOMP MEDICATION ADHERENCE REPORTING GUIDELINE (EMERGE)  121 
EMERGE consists of 21 items organized in 2 sections (see table 1). The first section includes 4 items 122 
outlining the minimum reporting criteria for medication adherence research. The following criteria 123 
need to be specified clearly:  (1) each phase of medication adherence studied (i.e., initiation, 124 
implementation, persistence); (2) a precise operational/working definition of each of the phases of 125 
medication adherence examined; (3) the methods of adherence measurement used for each phase, 126 
along with information on performance of the measure (i.e., validity, reliability, potential bias); and 127 
(4) the results of the analysis relevant to each phase. 128 
The second section of the guideline consists of 17 items that provide more detailed and specific 129 
information on the reporting of medication adherence. These are organized according to the 130 
reporting guidelines for experimental and observational studies (i.e., CONSORT, STROBE) (table 1). 131 
Building on the minimum reporting criteria, these items further highlight the importance of 132 
considering and distinguishing between the 3 phases of medication adherence (e.g., item 6: 133 
background/introduction; item 8: study objectives or hypotheses; item 15: statistical analysis; items 134 
19 & 21: discussion). Other items address areas that are often under- or unreported in adherence 135 
research. Item 7, for instance, addresses the need to clarify the rationale and/or framework guiding 136 
the study. Item 9 addresses information relevant to the setting where the adherence study was 137 
conducted (e.g., relevant characteristics of the healthcare system, healthcare organization and 138 
healthcare team); and item 11 requests information on routine care related to the management of 139 
medication adherence. For intervention studies (item 13), descriptions of both intervention and 140 
comparator groups are requested. Interventions should be described (if relevant) in the context of 141 
specified levels of the healthcare system (i.e., patient/caregiver, healthcare provider, healthcare 142 
organization and healthcare system). Further methodological details are requested pertaining to 143 
sampling (item 10 asks whether medication adherence is an eligibility criterion) and measurement 144 
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(item 12 addresses the potential impact of the adherence measure used on medication adherence). 145 
Information requested on statistical methods distinguishes between medication adherence as an 146 
outcome measure (item 15) and its use as an explanatory variable (item 16). Item 14 – an item 147 
relevant to implementation science – asks for information (when applicable) on any implementation 148 
strategy(34) that contributes to translation of a medication adherence intervention into clinical 149 
practice. EMERGE also reminds authors to include details in their results sections of possible links 150 
between non-participation and/or dropout either with medication non-adherence (item 17) or with 151 
sample characteristics relevant to it (item 18). 152 
[Please insert Table 1 here] 153 
DISCUSSION 154 
The ESPACOMP Medication Adherence Reporting Guideline (EMERGE) was developed to help 155 
researchers improve the quality of their reporting of medication adherence research, as this type of 156 
research is often methodologically weak (8, 35, 36) and suboptimally reported (11-13). While 157 
EMERGE has the advantage of being applicable to multiple study designs and methods focusing on 158 
medication adherence, its use will involve authors combining EMERGE items with other appropriate 159 
guidelines for health research reporting (e.g., STROBE, CONSORT, STaRi).  160 
EMERGE was developed through a consensus-based process involving a multidisciplinary group of 161 
international medication adherence experts. Using the Delphi surveys, these experts provided two 162 
rounds of feedback on the relevance and clarity of each included item. In addition to enhancing 163 
EMERGE’s relevance across diverse settings, their cooperation will facilitate guideline 164 
implementation.  165 
One of EMERGE’s major strengths is its grounding in a medication adherence conceptualization 166 
provided by a robust taxonomy.(10) Since its initial publication, this taxonomy, distinguishing 167 
between 3 phases of adherence (i.e., initiation, implementation,  persistence), has greatly benefitted 168 
the field of medication adherence research,(37, 38) and has been broadly adopted and widely 169 
cited.(39) EMERGE highlights the need to acknowledge and specify each of these 3 phases as being 170 
distinct parts of the process by which patients manage their medication regimens, that require 171 
specific considerations regarding their conceptualization, definition, measurement and analysis. 172 
EMERGE items – with the 4 minimum reporting criteria at their core – reflect essential yet often 173 
poorly handled or omitted elements of medication adherence research reporting. This includes the 174 
omission or suboptimal definition of key terms,(7, 11-13) the use of suboptimal measures,(15) and 175 
the use of inappropriate analytical methods.(11-13) EMERGE also highlights the need for other 176 
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relevant and often neglected aspects of adherence research reporting, e.g., a clearly-explained 177 
rationale or framework(16) and detailed information on the healthcare setting, including routine 178 
care.(15) 179 
EMERGE includes an item relevant to implementation science which is complementary to the STaRi 180 
reporting guideline,(23) in recognition of the importance of this discipline in advancing the field of 181 
medication adherence. While several promising interventions have been developed to improve 182 
adherence,(8, 35, 40) none have proved easy to implement in clinical practice. We do not suggest 183 
that every study can or should include an implementation component, but encourage researchers to 184 
plan studies with an eye towards potential implementation and sustainability. 185 
The main limitation affecting EMERGE’s development process is its primary focus on quantitative 186 
methodologies. However, the 4 minimum reporting criteria can also support qualitative and mixed-187 
methods research in guaranteeing that the research’s focus and relevant methodological aspects are 188 
aligned with the adherence taxonomy.(10) Additionally, although initial user testing demonstrated 189 
its easy applicability in combination with the main reporting guidelines, the advised combination of 190 
EMERGE with other reporting guidelines might initially seem challenging. Moreover, while following 191 
the 21 EMERGE items will yield thorough reporting of all matters common to medication adherence 192 
research, journal word count limits may sometimes restrict full reporting. Possible solutions include 193 
pre-publishing detailed methodologies and protocols and/or providing online-only 194 
supplements/appendices. Finally, although efforts were made to guarantee representation of all 195 
continents, there were fewer people from African and Asian countries in the international Delphi 196 
expert team.  197 
In addition to this article, dissemination and use of the EMERGE guidelines will be enhanced by 198 
information available on the EQUATOR webpage (www.equator-network.org, accessed: April 30th, 199 
2018) and the ESPACOMP website (www.espacomp.eu/emerge, accessed: April 30th, 2018), and 200 
endorsed by a range of related journals and professional organizations. ESPACOMP will support 201 
regular updates of EMERGE to ensure timely propagation of lessons learned from its use, along with 202 
new developments in medication adherence science. 203 
CONCLUSION 204 
Implementation of ESPACOMP Medication Adherence Reporting Guideline (EMERGE) is expected to 205 
enhance the quality of medication adherence research reporting via standardization, reducing 206 
research waste, accelerating progress in this and related fields, and ultimately, improving patient 207 
outcomes. 208 
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ROLE OF THE FUNDING SOURCE 209 
The study was funded by ESPACOMP. As the EMERGE steering committee is composed entirely of 210 
ESPACOMP members, they took the sole lead in designing EMERGE, in writing this paper, and in 211 
submitting it for publication. 212 
  213 
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page No. / 
line No. 
 Minimum reporting criteria    
 1a Phases of medication adherence: State the phase(s) of medication adherence studied 
(i.e. initiation, implementation, or persistence) and justify, where possible, the reasons 
the study focuses on the chosen phase(s). 
 
…… 
1b Operational definition: Provide the precise operational/working definition for each (of 




1c Measurement: Specify the method(s) of medication adherence measurement (e.g., self-
report, claims data, blood sampling, electronic monitoring). Consider each phase studied 
(i.e., initiation, implementation, or persistence), with details on the performance of the 




1d Results: Describe the results of the analysis appropriate to each (of the) phase(s) of 
medication adherence studied (i.e., initiation, implementation, or persistence). 
 
…… 
    
Abstract    
 2a Present in the abstract, in as much detail as space permits, information on the 4 




    
Background/introduction    
 3a Summarize what is known about the topic with appropriate reference to the phase(s) of 
medication adherence (i.e., initiation, implementation, and persistence). 
 
…… 
3b Describe the rationale and/or framework guiding the medication adherence study (e.g., 
theoretical framework, implementation science model). 
 
…… 
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Study objectives or hypotheses    
 4a State the study objectives or hypotheses with reference to the phase(s) of medication 
adherence studied and context (patient population and setting). 
 
…… 
    
Methods    
Design & participants 5a Describe the setting in which the study was conducted. Refer to factors relevant to 
medication adherence, such as characteristics of the healthcare system, the healthcare 
organization, and the healthcare team. 
 
…… 
5b State whether medication adherence was an eligibility criterion (e.g., inclusion/exclusion). 
If so, define the measures and rules used. 
 
…… 
5c Describe routine care related to the management of medication adherence (e.g., routine 




Measurement PLEASE REFER TO ITEM 1.C. IN ADDITION TO THE “MEASUREMENT” ITEM BELOW  
6a Measurement methods can themselves impact medication adherence (e.g., 




Intervention (where applicable) 7a For intervention and comparator groups, describe each relevant level of the medication 




7b Describe any implementation strategy that contributes to the translation (e.g., uptake, 





Statistical analysis 8a If medication adherence is an outcome variable, justify the statistical methods, given the 
characteristics of the variable (e.g., phases of medication adherence, data type, statistical 
distribution, data censoring, longitudinal dependence). 
 
…… 
8b If medication adherence is an explanatory variable, describe how it is related to the 
outcome(s) (e.g., causal pathway, temporal sequence). 
 
…… 
    
Running title: ESPACOMP Medication Adherence Reporting Guideline (EMERGE) 16 
 
Results    
 PLEASE REFER TO ITEM 1.D IN ADDITION TO THE “RESULTS” ITEMS BELOW  
9a Determine whether non-participation and/or dropout are associated with non-
adherence, and provide any relevant data. 
 
…… 
9b Present sample characteristics relevant to medication adherence (e.g., socio-
demographic, therapy-related, condition-related, patient-related, caregiver-related, 
healthcare team/healthcare system-related). 
 
…… 
    
Discussion    
 10a Discuss study strengths and limitations with reference to the phase(s) of medication 
adherence, where applicable (i.e., initiation, implementation, persistence). 
 
…… 
10b Discuss the study findings in the context of existing medication adherence evidence (e.g., 
theory, measurement, intervention effects). 
 
…… 
10c Discuss the generalizability (external validity) of the study findings with reference to the 





















Based on Vrijens et al. 2012. Br J Clin Pharmacol.(10) 
 
FIGURE 1:  Conceptualization of medication adherence 
 
